WO2014172653A3 - Anticorps anti-notch1 - Google Patents

Anticorps anti-notch1 Download PDF

Info

Publication number
WO2014172653A3
WO2014172653A3 PCT/US2014/034673 US2014034673W WO2014172653A3 WO 2014172653 A3 WO2014172653 A3 WO 2014172653A3 US 2014034673 W US2014034673 W US 2014034673W WO 2014172653 A3 WO2014172653 A3 WO 2014172653A3
Authority
WO
WIPO (PCT)
Prior art keywords
notch1
antibodies
notch1 antibodies
disorders
bind
Prior art date
Application number
PCT/US2014/034673
Other languages
English (en)
Other versions
WO2014172653A2 (fr
Inventor
Heidi Okamura
Alisa C. Bell
Ting Chen
Feng Jiang
Jie Lin
Ronan O'hagan
Laura POLING
Theresa PROIA
William M WINSTON, Jr.
Original Assignee
Aveo Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals, Inc. filed Critical Aveo Pharmaceuticals, Inc.
Publication of WO2014172653A2 publication Critical patent/WO2014172653A2/fr
Publication of WO2014172653A3 publication Critical patent/WO2014172653A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps monoclonaux qui se lient et inhibent les activités biologiques de Notch1 humaine. Les anticorps peuvent être utilisés pour traiter des maladies et des troubles de la prolifération cellulaire, y compris certaines formes de cancer, associés à l'activation ou à la surexpression de Notch1.
PCT/US2014/034673 2013-04-19 2014-04-18 Anticorps anti-notch1 WO2014172653A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361814168P 2013-04-19 2013-04-19
US61/814,168 2013-04-19

Publications (2)

Publication Number Publication Date
WO2014172653A2 WO2014172653A2 (fr) 2014-10-23
WO2014172653A3 true WO2014172653A3 (fr) 2015-01-08

Family

ID=50942790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/034673 WO2014172653A2 (fr) 2013-04-19 2014-04-18 Anticorps anti-notch1

Country Status (1)

Country Link
WO (1) WO2014172653A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091641A2 (fr) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions et procédés utilisés pour le diagnostic et le traitement du cancer
WO2008150525A1 (fr) * 2007-06-04 2008-12-11 Genentech, Inc. Anticorps anti-notch 1 spécifiques à nrr et ses procédés d'utilisation
WO2010059543A1 (fr) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Génération et caractérisation d’anticorps anti-notch pour utilisation thérapeutique et diagnostique
WO2011088215A2 (fr) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Agents de liaison notch1 et leurs procédés d'utilisation
WO2012003472A1 (fr) * 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anticorps anti-notch1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222590A1 (en) 2005-04-05 2006-10-05 Murray Robinson Directed complementation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091641A2 (fr) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions et procédés utilisés pour le diagnostic et le traitement du cancer
WO2008150525A1 (fr) * 2007-06-04 2008-12-11 Genentech, Inc. Anticorps anti-notch 1 spécifiques à nrr et ses procédés d'utilisation
WO2010059543A1 (fr) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Génération et caractérisation d’anticorps anti-notch pour utilisation thérapeutique et diagnostique
WO2011088215A2 (fr) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Agents de liaison notch1 et leurs procédés d'utilisation
WO2012003472A1 (fr) * 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anticorps anti-notch1

Also Published As

Publication number Publication date
WO2014172653A2 (fr) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2011143318A3 (fr) Anticorps anti-fgfr2
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MX2015007751A (es) Anticuerpos anti-gdf15.
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
WO2014197849A3 (fr) Anticorps anti-c10orf54 et leurs utilisations
EA201991214A1 (ru) Антитела против pd-1 и их композиции
WO2014159595A3 (fr) Anticorps humains dirigés contre nav1.7
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
WO2017031458A3 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
WO2013177055A3 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
WO2012145183A3 (fr) Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
WO2015050959A8 (fr) Anticorps anti-kits et leurs méthodes d'utilisation
WO2014108484A3 (fr) Thérapie de combinaison avec des anticorps anti-her3
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
TN2019000086A1 (en) Anti-il-33 antibodies and uses thereof
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
WO2011156617A3 (fr) Anticorps anti-egfr
EP3502141A4 (fr) Anticorps ciblant le facteur tissulaire, son procédé de préparation et son utilisation
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14730253

Country of ref document: EP

Kind code of ref document: A2